Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Krahl, A."'
Autor:
Dietger Niederwieser, Thomas Friedrich, Michael W. Deininger, Christina Franke, Evelin Hennig, Thomas Bumm, Erika Schmidt, Knut Krohn, Patricia Shepherd, Christel Müller, R. Krahl, Sabine Leiblein, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 101:1941-1949
Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor ofBcr-Abl, induces maj
Autor:
Martin Hildebrandt, Markus Y. Mapara, Peter Reichardt, Bernd Dörken, Ralf C. Bargou, Dorothea Krahl, Ida J. Körner
Publikováno v:
Blood. 89:337-344
We studied the efficiency of indirect tumor cell purging via enrichment of CD34+ hematopoietic progenitor cells from leukapheresis products (LP) in breast cancer patients based on immunomagnetic selection of CD34+ cells. Detection of tumor cells was
Autor:
Dietger Niederwieser, Rainer Krahl, Uwe G. Liebert, Elvira Edel, Claudia Wickenhauser, Marianne Hehme, Haifa Kathrin Al-Ali, Sabine Leiblein, Mark Westerman, Nadja Jaekel
Publikováno v:
Blood. 116:1307-1307
Abstract 1307 Iron homeostasis is controlled through a coordinated activity of multiple proteins through different signaling pathways with hepcidin being the central regulatory hormone. Iron overload in recipients of allogeneic hematopoietic cell tra
Autor:
Uwe G. Liebert, Haifa Kathrin Al-Ali, Rainer Krahl, Marianne Hehme, Mark Westerman, Sabine Leiblein, Ann-Kathrin Eisfeld, Dietger Niederwieser
Publikováno v:
Blood. 114:4047-4047
Abstract 4047 Poster Board III-982 Hepcidin (hep), a 25-amino-acid peptide, is the central regulator of iron homeostasis. Its transcription is upregulated by inflammatory cytokines and iron and is downregulated by iron deficiency, ineffective erythro
Autor:
Dietger Niederwieser, Oliver Pelz-Ackermann, Michael W. Deininger, Michael Cross, Haifa Kathrin Al-Ali, Rainer Krahl, Song-Yau Wang, Kathrin Wildenberger, Thoralf Lange
Publikováno v:
Blood. 110:2918-2918
Objectives: Acquired resistance to imatinib (IM) in patients with chronic myeloid leukaemia (CML) is frequently due to mutations of the BCR-ABL kinase domain (KD). Current thinking holds that this results from the selection of pre-existing mutant clo
Autor:
Rolf Marschalek, Claus Meyer, Arnold Ganser, Jürgen Krauter, Katharina Wagner, Hartmut Döhner, Gerhard Heil, Gerhard Ehninger, Dietger Niederwieser, Richard F. Schlenk, Rainer Krahl, Konstanze Döhner, Markus Schaich, Irina Schäfer
Publikováno v:
Blood. 108:16-16
Aberrations of the MLL gene on chromosome 11q23 occur in about 5–10% of adult patients with acute myeloid leukemia (AML). Most frequently, the MLL gene is fused to the genes AF9 on chromosome 9 or AF6 on chromosome 6 resulting in the translocation
Autor:
Christa Doering, Medical Student, Rainer Krahl, Elvira Edel, Sabine Schroeder, Ann-Kathrin Eisfeld, Haifa Kathrin Al-Ali, Dietger Niederwieser, Ralph Burkhardt
Publikováno v:
Blood. 106:3717-3717
Introduction: Iron metabolism plays an important role in hematopoiesis and immune response. In the present project, body iron stores and factors affecting iron storage such as HFE genotype and the number of blood transfusions were evaluated in patien
Autor:
Ruediger Alt, Michael W. Deininger, Ines Kovacz, Thomas Thielsen, Ralf Burckhardt, Christina Franke, Rainer Krahl, Dietger Niederwieser, Guido Zschau, Haifa Kathrin Al-Ali, Thoralf Lange, Sabine Leiblein
Publikováno v:
Blood. 106:1985-1985
Objectives: Most patients with chronic phase CML attain a complete cytogenetic response (CCR) to imatinib (IM) but BCR-ABL remains detectable by RT-PCR, indicating persistence of residual disease. One small study (Bhatia et al. Blood101(12):4701–7,
Autor:
Ralph Burkhardt, Dietger Niederwieser, Christa Doehring, Elvira Edel, Sabine Schroeder, Andrea Junghans, Ann-Kathrin Eisfeld, Uwe G. Liebert, Haifa Kathrin Al-Ali, Daniel Teupser, Rainer Krahl
Publikováno v:
Blood. 106:1812-1812
Risk factors for morbidity and treatment related mortality (TRM) following HCT have been well defined in retrospective analysis and prospective validations. These include disease-, recipient- and donor-specific characteristics, but not treatment rela
Autor:
Ralph Burkhardt, Andrea Junghans, Daniel Teupser, Ann-Kathrin Eisfeld, Dietger Niederwieser, Joachim Thiery, Sabine Schroeder, Haifa Kathrin Al-Ali, Rainer Krahl, Elvira Edel, Christa Doehring
Publikováno v:
Blood. 104:3684-3684
Introduction: A substantial proportion of European populations (10–40%) are heterozygous carriers (het) and 0.1–0.3% homozygos (homo) for the hemochromatosis gene (HFE). Patients (pts) with hematologic malignancies often receive multiple blood tr